NEOVAXSYN INC — Department of Health and Human Services SBIR Phase I: 102
NEOVAXSYN INC — SBIR Phase I award from Department of Health and Human Services.
Phase I SBIR feasibility signal
- Phase I awards fund proof-of-concept work. For capture teams, they mark early interest from Department of Health and Human Services in a technical approach.
- Watch for Phase II follow-ons from the same firm/topic family — that conversion path is where budgets and transition pressure rise.
- Obligated amount $300,000. Cross-check similar awards in the same agency and technology tags for going-rate context.
- Topic code 102 links this award to a solicitation family — search the same topic stem for incumbents and recompete timing.
- Amount
- $300,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 102
- Solicitation
- PHS-2022-1
- NAICS
- —
- Place of performance
- IA
- Period
- —
Description
Genetically Engineered Mice for Pre-clinical Evaluation of HIV Vaccine Candidates: The development of novel HIV candidate vaccines generally requires preclinical testing in animal models before proceeding to Phase I clinical trials. Multiple efforts have focused on developing and evaluating innovative platforms and formulations of HIV envelope (Env) immunogens for the induction and generation of a durable and broadly neutralizing antibody (bNAb) response. The goal of this program is to utilize genetically engineered mouse models, such as human immunoglobulin KI or other transgenic mice expressing relevant human genes, to accelerate testing and development of HIV vaccine candidates.